Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect

Pharmacokinetics of liquiritigenin, a candidate for inflammatory liver disease, and its two glucuronide conjugates, M1 and M2, were evaluated in rats. The hepatic and gastrointestinal first-pass effects of liquiritigenin were also evaluated in rats. After oral administration of liquiritigenin at a dose of  20 mg kg−1, 1.07% of the dose was not absorbed from the gastrointestinal tract up to 24 h, and the F-value was only 6.68%. In vitro metabolism of liquiritigenin in S9 fractions of rat tissues showed that the liver and intestine were major tissues responsible for glucuronidation of liquiritigenin. The hepatic and gastrointestinal first-pass effects of liquiritigenin were approximately 3.67% and 92.5% of the oral dose, respectively. Although the hepatic first-pass effect of liquiritigenin after absorption into the portal vein was 57.1%, the value was only 3.67% of the oral dose due to extensive gastrointestinal first-pass effect in rats. Therefore, the low F-value of liquiritigenin in rats was primarily attributable to an extensive gastrointestinal first-pass effect although liquiritigenin was well absorbed. Compared with rats, the higher F-value of liquiritigenin could be expected in humans.

[1]  S. Sohn,et al.  Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up. , 2009, Journal of pharmaceutical sciences.

[2]  M. Lee,et al.  Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. , 2009, Journal of pharmaceutical sciences.

[3]  Young Woo Kim,et al.  Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[4]  M. Lee,et al.  Dose‐independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first‐pass effects to low bioavailability , 2008, Biopharmaceutics & drug disposition.

[5]  S. G. Kim,et al.  Anti‐inflammatory effects of liquiritigenin as a consequence of the inhibition of NF‐κB‐dependent iNOS and proinflammatory cytokines production , 2008, British journal of pharmacology.

[6]  Kang Hee Eun,et al.  Determination of an Agent for the Inflammatory Liver Disease, Liquiritigenin, in Rat Plasma, Urine, and Various Tissue Homogenates by High-performance Liquid Chromatography , 2008 .

[7]  Young Woo Kim,et al.  Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine. , 2006, Chemico-biological interactions.

[8]  W. L. Chiou,et al.  Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism , 1983, Journal of Pharmacokinetics and Biopharmaceutics.

[9]  W. L. Chiou,et al.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  C. Yang,et al.  Cytoprotective effects of Glycyrrhizae radix extract and its active component liquiritigenin against cadmium-induced toxicity (effects on bad translocation and cytochrome c-mediated PARP cleavage). , 2004, Toxicology.

[11]  C. Klaassen,et al.  Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[12]  K. Mizojiri,et al.  Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. , 2003, Drug metabolism and pharmacokinetics.

[13]  J. Kwon,et al.  Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. , 2000, Biopharmaceutics & drug disposition.

[14]  C. Shim,et al.  Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7, after intravenous and oral administration to rats, rabbits, and dogs. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[15]  Y. Sugiyama,et al.  Multiple systems for the biliary excretion of organic anions in rats: liquiritigenin conjugates as model compounds. , 1994, The Journal of pharmacology and experimental therapeutics.

[16]  Y. Sugiyama,et al.  Identification of tissues responsible for the conjugative metabolism of liquiritigenin in rats: an analysis based on metabolite kinetics. , 1993, Biological & pharmaceutical bulletin.

[17]  H. Shimamura,et al.  Biliary and Urinary Metabolites of Liquiritin in Rats , 1990 .

[18]  W. L. Chiou,et al.  Pharmacokinetics of drugs in blood. I. Unusual distribution of gentamicin. , 1981, Biopharmaceutics & drug disposition.

[19]  E. Mimnaugh,et al.  Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. , 1975, Drug metabolism and disposition: the biological fate of chemicals.